Cardinal Health (CAH) Q1 2027 Earnings Call Transcript

Cardinal Health reported fiscal Q1 2027 revenue of $67.5 billion, up 5%, non-GAAP diluted EPS of $3.26, up 28%, and record quarterly operating income of $1.0 billion, up 17%. It raised fiscal 2027 EPS guidance to $12.80–$13.00 from $12.40–$12.60, alongside higher profit-growth guidance for Pharmaceutical and Other. Strong specialty demand and growth businesses were partly offset by a 400-basis-point IRA-related revenue headwind; management said sustained high petroleum costs tied to the Iran conflict put GMPD profit toward the low end of its $200 million–$220 million guidance range. The company repurchased $500 million of shares during the quarter and ended it with $5.3 billion in cash.

Analysis

The key risk is extrapolating Q1’s earnings pace: management explicitly expects moderation in Q2–Q3 as renewal timing effects roll through and the Solaris acquisition is lapped. The raised full-year outlook is more persuasive than the quarter alone, but its durability depends on specialty and generics strength persisting; the GLP-1 volume contribution is not a substitute for underlying unit economics, particularly with IRA-related pricing pressure already offsetting much of the reported revenue lift. The lower tax-rate outlook and reduced share count also support EPS, so not all per-share growth should be capitalized as operating acceleration.

Long-dated CVS contract visibility reduces renewal risk for Cardinal Health, but says little about contract profitability or bargaining power. The main near-term operational asymmetry is GMPD: high petroleum costs pressure transport economics, while the company has not raised that segment’s outlook. A sustained oil shock could make the consolidated guidance raise look less broad-based. Over 6–18 months, automation and specialty integration may improve resilience and mix, but the call provides no quantified savings or returns; treat those as options, not current earnings.

Contrarian risk: the market may reward the raised guide while underweighting the disclosed quarterly deceleration. The Eli Lilly real-world evidence study is strategically useful but not evidence of near-term product revenue. No valuation or post-earnings price data are supplied, so a chase or price target is not justified.

Key Decisions for Investors

• Do not chase an opening spike in Cardinal Health; consider adding only after the market prices in the stated Q2–Q3 moderation, and reassess against quarterly pharmaceutical segment profit and full-year guidance.
• Set an alert on petroleum prices and GMPD profit commentary. A sustained rise alongside movement toward the low end of the $200–$220 million segment-profit outlook would weaken the earnings-quality thesis; improving transport costs or GMPD execution would reduce that risk.
• Treat CVS renewal as a visibility positive for Cardinal Health, not proof of better economics for CVS or Cardinal Health. Verify contract economics and renewal-related profit timing before making a CVS read-through trade.
• Do not trade LLY on the research collaboration alone. Look for evidence of commercial scale or measurable financial contribution before treating it as an earnings catalyst.